Medindia

X

Reportlinker Adds the Russian Pharmaceutical Market Outlook to 2014: Policy Environment, Market Structure, Competitive Landscape, Growth Opportunities

Wednesday, April 7, 2010 Research News J E 4
Advertisement
NEW YORK, April 6 Reportlinker.com announces that a new market research report is available in its catalogue:

The Russian Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities

http://www.reportlinker.com/p0186704/The-Russian-Pharmaceutical-Market-Outlook-to-2014-Policy-environment-market-structure-competitive-landscape-growth-opportunities.html

Russia's well educated and low cost workforce is one of the main attraction for investors all over the world. According to recent statistics, Russia's population (which is currently about 141m) is steadily declining at a rate of around 0.4%. Thus, the government is trying to remedy this through several immigration policies and federal programs such as stimulating birth rates and reducing mortality.

Russia has been one of the fastest growing emerging pharmaceutical markets in the world in recent years. The Russian healthcare industry is also experiencing robust growth which is primarily driven by several initiatives by the government such as improvement in primary care, efficient implementation of health insurance and an increase in healthcare financing.

Russia is an ideal branded generic market, as consumers are willing to pay higher prices for brands associated with quality. This is due to the fact that several domestic manufacturers operate plants that are not GMP (good manufacturing practice) compliant. As a result, foreign pharmaceutical companies have been effective at driving growth by promoting their brands over local products.

Russians are known to under spend on pharmaceutical products both in nominal and relative terms. In terms of public and out-of-pocket spending on pharmaceuticals, the Russian pharmaceutical market still lags behind the other emerging and developed countries. Out-of-pocket expenditure on pharmaceuticals accounts for the overwhelming majority of sales in Russia (which is much higher as compared to other OECD countries).

The Russian Pharmaceutical Market Outlook to 2014 provides comprehensive coverage of the Russian pharmaceutical market, market structure, pricing and regulation, and includes detailed epidemiological analyses of the common indications/risk factors. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share, sales forecast and competitive landscape for the major players in Russia. Furthermore, the report highlights the key market and R&D trends that may influence treatment sales, with a thorough analysis of the competitive dynamics of leading brands and indications in Russia. This will enable the reader to identify growth trends, key drug classes and leading players through to 2014.

Key features of this report

Scope of this report

- Develop insights for the Russian pharmaceutical market, pricing & regulation, healthcare system and detailed epidemiological status of the common indications/risk factors in the country

- Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive challenges in the Russian market

- Gain up-to-date competitive intelligence across a wide-range of marketed products, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Russian pharmaceutical market

- Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities in Russia

Key Market Issues

- Stringent drug pricing regulation in Russia might create an opportunity for local manufacturers: In August 2009, the Russian Ministry of health presented a draft guideline on optimizing the price regulation of essential and life-saving medicines in the country. According to the draft, companies have to register the prices of essential and vital medicines in Roubles (Russian currency) from January 01, 2011 and introduce a maximum trade mark-ups for both locally manufactured and imported drugs in Russia.

- Influvir and Pandeflu among two swine flu vaccines to receive Russian approval: In October 2009, Roszdravnadzor, Russia's federal service on surveillance in healthcare and social development approved two domestic H1N1 flu vaccines Influvir and Pandeflu under a fast-track procedure. The approval was solely based on the safety and tolerability of the vaccine with no major side-effects. Influvir is a live monovalent vaccine for intranasal administration, while Pandeflu is an inactivated adsorbed monovalent sub-unit vaccine for injection.

- Neuronascent's collaboration agreement with ChemRar will find new molecules in neurodegenerative diseases: In November 2009, Neuronascent (a US biotech company) and ChemRar (a Russian biotech start-up) signed a discovery agreement under which Neuronascent will screen ChemRar's certain pathway inhibitors using its technology for identifying neurogenic and neuroprotective drug candidates. Both the companies also decided to evaluate co-development opportunities for funding and future commercialization of their products.

Key findings from this report

- The Russian pharmaceutical market was valued at around $6bn in sales in 2008. Despite several changes in the DLO system (state restricted reimbursement program) which was introduced to promote increased utilization of domestically manufactured drugs, imported drugs accounted for substantial portion of sales in the Russian market.

- Economic growth and stability have increased the attractiveness of the Russian pharmaceutical market to foreign companies. More recently, Russia also became a favored destination for outsourcing of clinical trials.

- Drug suppliers in the Russian pharmaceutical market are mainly manufacturers of APIs. However many large pharmaceutical players also have a chemical manufacturing unit in this country. For example Merck & Co. has its own chemical division in Russia.

- Drugs representing cardiovascular and alimentary canal & metabolic disorders held dominant position in Russian pharmaceutical market (with as many as six products in the top 10). However, the top 10 brands contributed only 7.3% in terms of market share in 2008, with 'others' accounting for a substantial share of 92.7%.

- Nycomed's Actovegin (a cerebral and peripheral vasotherapeutic agent) and Pharmstandard's Arbidol (one of the leading OTC drug for influenza) led the Russian pharmaceutical market in 2008.

Key questions answered

- What will be the major growth indications and the accompanying growth drivers in the Russian pharmaceutical industry over the next 5 years?

- Which were the leading players in the Russian pharmaceutical market (both multinational and domestic) in 2008?

- How have recent launches from companies such as Novartis, Sanofi-Aventis, Servier, Bayer, Pharmstandard and Gedeon Richter performed in the market place?

- Which products will be the future growth drivers for the Russian pharmaceutical market?

- Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2008-14?

Companies mentioned

Bayer , Gedeon Richter , Novartis , Pharmstandard , Sanofi-Aventis , Servier

Table of Contents

The Russian pharmaceutical market outlook to 2014

Executive summary 10

The Russian macroeconomic environment 10

The Russian healthcare system 11

Market analysis 12

Competitive landscape 13

Chapter 1 Scope and methodology 16

Scope 16

Methodology 16

Chapter 2 The Russian macroeconomic environment 18

Summary 18

Introduction 19

Demographic trends in Russia 20

Economic landscape of Russia 21

Disease burden 23

Healthcare spending 25

Chapter 3 The Russian healthcare system 28

Summary 28

Introduction 29

Pharmaceutical spending 30

Intellectual property regime 31

Pricing and reimbursement 32

Healthcare reform in Russia 35

Russian pharmaceutical market: 2020 vision 36

Russia: a clinical trial destination 37

Chapter 4 Market analysis 40

Summary 40

Introduction 41

Comparative dynamics of emerging pharmaceutical markets 42

Key recent events in Russia 44

Stringent drug pricing regulation in Russia might create an opportunity for local manufacturers 44

The $24m financial support by the Global Fund will help to fight HIV/AIDS in Russia 45

Lipoxen to test pharmaceutical drugs with Russia's Pharmsynthez 46

Neuronascent signs collaboration agreement with ChemRar to find new molecules in neurodegenerative diseases 46

Influvir and Pandeflu among two swine flu vaccines to receive Russian approval 47

Russian OTC pharmaceutical market 47

Therapeutic area analysis 48

Therapeutic area sales forecast 50

Leading product dynamics 51

Actovegin: Nycomed 52

Arbidol: Pharmstandard 53

Meronem: AstraZeneca 53

Essentiale N: Sanofi-Aventis 53

Viagra: Pfizer 54

Linex: Novartis 54

Mexidol: Farmasoft 54

Amoksiklav: Novartis 54

Heptral: Hospira 55

Mildronat: Grindex 55

Leading product sales forecast 56

The generic pharmaceutical market in Russia 57

Generic sales performance by therapy area 58

Leading drug classes in Russian generic market 59

Leading generic products in Russia 60

Chapter 5 Competitive landscape 62

Summary 62

Introduction 63

Competitive positioning of the leading players in the Russian pharma market 64

Detailed analysis of leading players in the Russian pharmaceutical market 65

Novartis 65

Overview 65

Sales focus by therapeutic category 67

Marketed product portfolio 68

Novartis' pipeline focus 70

Strategic growth analysis 71

Sanofi-Aventis 73

Overview 73

Sales focus by therapeutic category 74

Marketed product portfolio 76

Sanofi-Aventis' pipeline focus 78

Strategic growth analysis 78

Servier 81

Overview 81

Sales focus by therapeutic category 81

Marketed product portfolio 82

Servier's pipeline focus 84

Strategic growth analysis 84

Bayer 85

Overview 85

Sales focus by therapeutic category 86

Marketed product portfolio 87

Bayer's pipeline focus 89

Strategic growth analysis 90

Pharmstandard 92

Overview 92

Sales focus by therapeutic category 93

Marketed product portfolio 94

Pharmstandard's pipeline focus 95

Strategic growth analysis 96

Gedeon Richter 98

Overview 98

Sales focus by therapeutic category 98

Marketed product portfolio 99

Gedeon Richter's pipeline focus 101

Strategic growth analysis 102

Competitive positioning of leading generics players in Russia 104

Chapter 6 Appendix 107

Anatomical therapeutic classification (ATC) 107

A: Alimentary tract and metabolism 107

B: Blood and blood-forming organs 107

C: Cardiovascular system 107

D: Dermatologicals 107

G: Genito-urinary system and sex hormones 108

H: Systemic hormonal preparations 108

J: General anti-infectives systemic 108

K: Hospital solutions 108

L: Antineoplastic and immunomodulating agents 108

M: Musculoskeletal system 108

N: Nervous system 109

P: Parasitology 109

R: Respiratory system 109

S: Sensory organs 109

T: Diagnostic agents 109

V: Various 109

Forecast factors 110

Glossary 111

Index 112

List of Figures

Figure 2.1: Russian GDP distribution across different sectors, 2009 23

Figure 2.2: Comparison of healthcare expenditure across the pharmerging markets 26

Figure 4.3: Pharmerging market share breakdown by 2008 sales 43

Figure 4.4: Comparative dynamics of pharmerging markets, 2008 43

Figure 4.5: Top 10 drug classes in the Russian generic pharmaceutical market, 2008 59

Figure 5.6: Novartis' Russian pharmaceutical sales by therapy area, 2008 67

Figure 5.7: Sanofi-Aventis' Russian pharmaceutical sales by therapy area, 2008 74

Figure 5.8: Servier's Russian pharmaceutical sales by therapy area, 2008 82

Figure 5.9: Bayer's Russian pharmaceutical sales by therapy area, 2008 87

Figure 5.10: Pharmstandard's Russian pharmaceutical sales by therapy area, 2008 93

Figure 5.11: Gedeon Richter's Russian pharmaceutical sales by therapy area, 2008 99

Figure 5.12: Positioning of top 10 generics players in Russia, 2008 104

Figure 5.13: Russian value and volume sales for generic pharmaceutical market, 2008 106

List of Tables

Table 2.1: Russia's key demographic indicators, 2009 20

Table 2.2: Key economic metrics in Russia, 2009 21

Table 2.3: Forecast epidemiology of common risk factors in Russia, 2008-14 24

Table 4.4: Russian pharmaceutical sales by therapy area, 2008 49

Table 4.5: Russian pharmaceutical market sales forecast by ATC code, 2008-14 51

Table 4.6: Leading brands in the Russian pharmaceutical market, 2008 52

Table 4.7: Leading products sales forecast, 2008-14 56

Table 4.8: Russian generic pharmaceutical sales by therapy area, 2008 58

Table 4.9: Leading generic drugs in the Russian pharmaceutical market, 2008 60

Table 5.10: Leading companies in the Russian pharmaceutical market based on prescription sales, 2008 64

Table 5.11: Top five domestic companies in Russia based on prescription sales, 2008 65

Table 5.12: Novartis' leading brands in Russian pharmaceutical market, 2008 68

Table 5.13: Sanofi-Aventis' leading brands in Russian pharmaceutical market, 2008 76

Table 5.14: Servier's leading brands in Russian pharmaceutical market, 2008 83

Table 5.15: Bayer's leading brands in Russian pharmaceutical market, 2008 88

Table 5.16: Bayer's key pipeline drugs in Russia, 2010 90

Table 5.17: Pharmstandard's leading brands in Russian pharmaceutical market, 2008 94

Table 5.18: Gedeon Richter's leading brands in Russian pharmaceutical market, 2008 100

Table 5.19: Leading generics players in Russian pharmaceutical market, 2008 105

To order this report:

Pharmaceutical Industry: The Russian Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

-- Macroeconomic environment in Russia includes the demographic trends, economic landscape, disease burden and healthcare spending -- Russian healthcare system involving the pharmaceutical spending, intellectual property regime, pricing and reimbursement, healthcare reforms, and recent development in the healthcare sector -- Overview of the Russian pharmaceutical market covering comparative dynamics of emerging pharmaceutical market, key recent events, Russian OTC pharmaceutical market, therapeutic area analysis, leading product dynamics, generic drug market and the overall market forecast through 2014 -- Forecasts and analysis of the leading products in the Russian pharmaceutical market over the period 2008-14 spread across major indications and classes of treatments

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Sinovac Reports Unaudited Fourth Quarter and Preli...
S
Reportlinker Adds Pipeline Insight: Gastrointestin...